Aficamten is under clinical development by Cytokinetics and currently in Phase III for Hypertrophic Cardiomyopathy. According to GlobalData, Phase III drugs for Hypertrophic Cardiomyopathy does not have sufficient historical data to build an indication benchmark PTSR for Phase III. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the Aficamten LoA Report. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Cytokinetics is a biopharmaceutical company with a focus on the discovery, development, and commercialization of muscle activators and muscle inhibitors as potential treatments for debilitating diseases wherein muscle performance is affected. The company develops small molecule drug candidates which is designed to affect muscle function and contractility. Cytokinetics is developing aficamten, a next-generation cardiac myosin inhibitor, to treat hypertrophic cardiomyopathy (HCM). It is also developing reldesemtiv, a fast skeletal muscle troponin activator, for the treatment of ALS patients. The company has licensing and collaboration agreements with Amgen, Ji Xing, and Astellas for advancing its drug candidates. Cytokinetics is headquartered in South San Francisco, California, the US.
For a complete picture of Aficamten’s drug-specific PTSR and LoA scores, buy the report here.